MENU
+Compare
NVSEF
Stock ticker: OTC
AS OF
Oct 14 closing price
Price
$131.48
Change
+$1.48 (+1.14%)
Capitalization
253.25B

NVSEF stock forecast, quote, news & analysis

Novartis develops and manufactures innovative drugs... Show more

NVSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for NVSEF with price predictions
Oct 16, 2025

NVSEF's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for NVSEF turned positive on October 03, 2025. Looking at past instances where NVSEF's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 01, 2025. You may want to consider a long position or call options on NVSEF as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVSEF advanced for three days, in of 107 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NVSEF moved out of overbought territory on October 07, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where NVSEF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVSEF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NVSEF broke above its upper Bollinger Band on October 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NVSEF entered a downward trend on October 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.061) is normal, around the industry mean (9.950). P/E Ratio (19.165) is within average values for comparable stocks, (24.516). Projected Growth (PEG Ratio) (1.368) is also within normal values, averaging (2.064). Dividend Yield (0.030) settles around the average of (0.028) among similar stocks. P/S Ratio (4.751) is also within normal values, averaging (3.571).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NVSEF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Dividends

NVSEF paid dividends on March 08, 2021

Novartis AG NVSEF Stock Dividends
А dividend of $3.17 per share was paid with a record date of March 08, 2021, and an ex-dividend date of March 04, 2021. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 93.98B. The market cap for tickers in the group ranges from 72.83K to 719.7B. LLY holds the highest valuation in this group at 719.7B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 0%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 19%. MIRA experienced the highest price growth at 29%, while CHJTF experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 87%. For the same stocks of the Industry, the average monthly volume growth was 74% and the average quarterly volume growth was 29%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 32
P/E Growth Rating: 65
Price Growth Rating: 78
SMR Rating: 100
Profit Risk Rating: 77
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
NVSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Lichtstrasse 35
Phone
+41 613241111
Employees
76057
Web
https://www.novartis.com